An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
Two new studies from the largest single-center cohort of Susac syndrome patients reveal that small-vessel infarcts on MRI predict vision loss from retinal artery occlusions, and the complete disease triad may affect up to 70% of patients. The findings were presented at the International Stroke Conference 2026.
The FDA granted Breakthrough Device Designation to TOBY Inc.'s urine-based Alzheimer's diagnostic test and Instanosis Inc.'s Xylazine Rapid Test (Urine), accelerating development of both non-invasive diagnostic technologies.
Researchers found a schizophrenia biomarker, CACNA2D1, and corrected brain circuit problems in mice. A grin2a gene mutation disrupts belief-updating; new cholinergic antipsychotics are emerging.
People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07772947 |
Effects of Hyperbaric Oxygen Combined With Aerobic Exercise on Working Memory Among Stroke Patients |
COMPLETED | NA |
| NCT07764250 |
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive Impairment |
RECRUITING | NA |
| NCT07760545 |
Reliability In Neurocognitive Telemedicine Screening (RING) |
RECRUITING | |
| NCT07742605 |
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performance |
COMPLETED | NA |
| NCT07729969 |
Early Cognitive Interventions in Digital Format for Cancer Survivors |
RECRUITING | NA |
| NCT07723131 |
Structural and Clinical Predictors of Cognitive Impairment After Surgical Treatment for Ruptured Cerebral Aneurysms |
NOT_YET_RECRUITING | |
| NCT07718321 |
Feasibility and Acceptability of StimolIrpinia for Cognitive Rehabilitation After Severe Acquired Brain Injury |
RECRUITING | NA |
| NCT07717567 |
Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression |
RECRUITING | |
| NCT07711834 |
Exercise and PPARGC1A rs8192678 in Older Adults With Type 2 Diabetes and Cognitive Impairment |
COMPLETED | NA |
| NCT07711171 |
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment |
RECRUITING | PHASE4 |
